Recent real-world data from Italy underscores the clinical utility of **Melflufen in RRMM treatment** for patients with few remaining options. Multiple myeloma management has advanced significantly, yet triple-class refractory cases present a formidable challenge. In this context, researchers explored the effectiveness of melflufen plus dexamethasone outside of formal clinical trials. Their findings provide valuable insights into managing heavily pretreated populations in a rapidly evolving therapeutic landscape.

### Outcomes of Melflufen in RRMM Treatment
A single-center study in Bologna analyzed 17 relapsed/refractory multiple myeloma (RRMM) patients. These individuals received melflufen-dexamethasone between December 2021 and July 2025. The results were encouraging, showing an overall response rate (ORR) of 41%. Furthermore, the median progression-free survival (mPFS) reached 3.7 months for the entire cohort. Specifically, responders achieved a much higher mPFS of 9.0 months. These outcomes suggest that the therapy offers a meaningful bridge for patients refractory to standard care.

### Safety and Tolerability Considerations
Safety remains a primary concern for clinicians treating fragile patients. This study reported that grade 3 or higher hematologic toxicities were common. Specifically, neutropenia and thrombocytopenia occurred in 53% of patients, while 35% experienced anemia. However, nonhematologic adverse events like fatigue and infections were less frequent. Importantly, no secondary primary malignancies occurred during the follow-up period. This safety profile appears manageable through dose adjustments and supportive care.

### Clinical Positioning for Elderly Patients
The study highlights that melflufen-dexamethasone is a viable option for elderly and fragile patients. These individuals often cannot tolerate more aggressive immunotherapies. Moreover, the regimen preserves access to future T-cell redirecting therapies. Consequently, it addresses a significant unmet need for patients who are not ideal candidates for cutting-edge treatments.

### Frequently Asked Questions

What is the overall response rate for Melflufen in triple-class refractory patients?

In a real-world study of 17 patients, the overall response rate for melflufen-dexamethasone was 41%, demonstrating efficacy even in heavily pretreated populations.

What are the most common side effects associated with Melflufen treatment?

The most frequent side effects are hematologic toxicities, including neutropenia (53%), thrombocytopenia (53%), and anemia (35%). Nonhematologic events such as infections and fatigue occur less frequently.

Is Melflufen a suitable option for elderly multiple myeloma patients?

Yes, real-world data indicates that Melflufen is effective and has a manageable safety profile in elderly and fragile patients who may not be candidates for more intensive immunotherapies.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. The information provided is based on specific research findings and should not replace the judgment of a healthcare professional. Refer to the latest local and national guidelines for clinical practice.

References

1. Mancuso K et al. Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape. Eur J Haematol. 2026 Mar 11. doi: 10.1111/ejh.70156. PMID: 41813608.


2. European Medicines Agency (EMA). Pepaxti (melphalan flufenamide) Summary of Product Characteristics.


3. Richardson PG et al. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma (HORIZON). J Clin Oncol. 2021;39(7):757-767.